Physician profile
Robert G Perez
NPI 1699866061
$1,782.85
in general payments reported to CMS, 2019-2025
13 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.27 · 2020: $337 · 2022: $191 · 2023: $502 · 2024: $379 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,228.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $774.57 | 2019-2024 | Da Vinci Surgical System |
| Mallinckrodt Hospital Products INC. | $216.63 | 2023-2025 | Acthar |
| Celgene Corporation | $196.70 | 2023-2024 | Reblozyl |
| Calliditas Therapeutics US INC. | $155.12 | 2023-2025 | Tarpeyo |
| Janssen Pharmaceuticals, INC | $109.37 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $98.58 | 2023-2024 | Farxiga |
| Amgen INC. | $53.82 | 2024-2025 | Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $47.28 | 2025 | |
| Glaxosmithkline, LLC. | $38.61 | 2022-2023 | Jesduvroq, Benlysta |
| Travere Therapeutics, INC. | $28.61 | 2023 | |
| Vantive US Healthcare LLC | $25.39 | 2025 | Renal - Pd |
| Ardelyx, INC. | $24.37 | 2024 | Ibsrela |
| Akebia Therapeutics INC | $13.80 | 2025 | Vafseo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.